Our Products
We are leaders in the market for providing best range of Famotidine, Ketorolac Tromethamine Powder, Isoniazid, INDINAVIR and Lisinopril
Famotidine is A histamine H2-receptor Antagonist that Inhibits stomach Acid production. It is Commonly Used in the Treatment Of peptic Ulcer disease And gastroesophageal Reflux disease. Unlike cimetidine, the First H2antagonist, Famotidine Has No Effect On The cytochrome P450 enzyme System, and Does Not Appear To interact with other Drugs. Relief Of heartburn, Acid Indigestion, and Sour Stomach Treatment For gastric and duodenal Ulcerstreatment for Pathologic Gastrointestinal Hypersecretory Conditions such As zollinger-ellison Syndrome and multiple Endocrine Adenomastreatment. For gastroeso- Phageal Reflux (gerd)treatment For esophagitis Prevention Of nsaid Induced Peptic Ulcers. Famotidine is also Given to Dogs and Cats with Acid Reflux. famotidine Has Been Used in Combination with An H1 Antagonist to Treat and Prevent Urticaria caused By An Acute Allergic Reaction.
Details
Ketorolac tromethamine is a pyrrolizine carboxylic acid derivative structurally related to indomethacin. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity. Ketorolac tromethamine is the tromethamine salt of ketorolac, a synthetic pyrrolizine carboxylic acid derivative with anti-inflammatory, analgesic & antipyretic properties.ketorolac tromethamine, a non-selective inhibitor of the cyclooxygenases (cox), inhibits both cox-1 & cox-2 enzymes. This agent exerts its anti-inflammatory effect by preventing conversion of arachidonic acid to prostaglandins at inflammation site mediated through inhibition of cox-2, which is undetec- table in most tissues but is up-regulated at the inflammation sites. Since cox-1 is expressed virtually in all tissues, inhibition of cox-1 enzyme by this agent prevents normal state production of prostaglandins, which plays housekeeping roles in the protection of the gastrointestinal tract, regulating renal blood flow, and functioning in platelet aggregation. As a result, inhibition of cox-1 is usually associated with adverse effects such as gastrointestinal toxicity and nephrotoxicity.